BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins  University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BC Extra | Oct 31, 2019
Company News

Backed by Morningside, Pinteon’s first clinical program targets toxic tau isoform

After five years performing preclinical work with funding from Morningside Ventures, Pinteon has emerged from stealth mode just as its lead program has reached the clinic to treat tauopathy-associated neurodegenerative diseases. Based on research by...
BC Innovations | Jan 29, 2019
Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting IRAK1 or its activator PIN1 could help treat radiotherapy-resistant, p53-mutant head and neck cancers and other cancers. In patients with...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting PIN1 could help treat pancreatic ductal adenocarcinoma (PDAC). In patients, PIN1 levels were higher in tumor samples than in adjacent normal tissue samples...
BC Innovations | Aug 27, 2015
Distillery Therapeutics

Therapeutics: Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1)

Cancer INDICATION: Cancer In vitro studies identified a cell-permeable peptide inhibitor of PIN1 that could help treat cancer. Screening of a library of analogs of a PIN1-inhibiting peptide in a cell-free PIN1-binding assay identified a...
BC Innovations | Nov 29, 2012
Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Nonalcoholic steatohepatitis (NASH) Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1) Mouse studies suggest inhibiting PIN1 could help treat and prevent NASH. In mice fed...
BC Innovations | Apr 26, 2012
Targets & Mechanisms

TAU's cease and de-cis-t letter

Although it is well established that phosphorylated microtubule-associated protein-t contributes to the pathology of Alzheimer's disease, antibodies against the target have so far been ineffective and have thus been relegated to research-only use. Now, researchers...
BC Innovations | Apr 12, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Phosphorylated-t 231 (p-t 231) In vitro and mouse studies identified antibodies against the cis conformation of p-t 231 that could help treat...
BC Innovations | Feb 17, 2011
Tools & Techniques

Engineering protein stability

Two American teams have proposed distinct strategies to improve the stability of recombinant proteins. The techniques could be used to increase the manufacturing yield, shelf life and potentially the duration of efficacy of biologics, including...
BC Innovations | Dec 17, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); amyotrophic lateral sclerosis (ALS); Parkinson's disease (PD) Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1) A study in rat neurons suggests that inhibiting...
Items per page:
1 - 10 of 20